Events
The U.S. Justice Department announced yesterday that it will not challenge the merger of CVS Health Corp and health insurer Aetna.
On June 11, 2018, FDA Commissioner Scott Gottlieb released a complementary framework for gene therapies, noting that in the last 12 months the agency has approved three different gene therapy products. “This reflects the rapid advancements in this field,” Gottlieb stated.
Schultz Chan, the former director of biostatistics at Cambridge-based Akebia Therapeutics and Songjiang Wang, a director of statistical programming at Merrimack Pharmaceuticals (MACK) were convicted of insider trading by a federal grand jury in Boston.
Pharma giant Pfizer will reorganize itself into three different business units that will include an innovative medicines business that includes a new hospital-focused segment for anti-infectives and sterile injectables.
Idera Pharmaceuticals and BioCryst Pharmaceuticals originally planned on January 22, 2018 to merge the two companies. Now the two companies announced the deal has been terminated.
It’s hard to believe 2018 is half over. There have been plenty of interesting and important stories in the biopharma space this year. Here’s a look at our top 10 stories so far, counting down from 10 to the number one story.
An independent Data Safety Monitoring Board (DSMB) recommended that Titan Pharmaceuticals’ Phase I/II trial of its ropinirole implant for Parkinson’s disease continue with a second cohort of patients. However, the company has decided to temporarily halt the study and focus on another asset.
Shares of Galapagos NV fell more than 15 percent Thursday afternoon and continued to fall in premarket trading after the Belgium-based company said AbbVie opted to walk away from its cystic fibrosis collaboration.
Switzerland-based Novartis announced it plans to spin off Alcon, its eye care division, into a separately-traded standalone company.
Amazon is making a foray into an online pharmacy. Amazon is buying PillPack, an online pharmacy that allows customers to buy drugs in pre-made doses.
PRESS RELEASES